Effect of Paricalcitol Over Vessel Wall

• Status: Terminated
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Effice Servicios Para la Investigacion S.L.
• Collaborators: Fundació Renal Jaume Arnó; Jaume Arnó Renal Foundation
• Treatments: Ergocalciferols

Criteria

Inclusion Criteria:

• Patients aged between 50 and 75 years.

• Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD).

• Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml.

• Plasma concentrations of 25 (OH) vitamin D <30 ng/ml.

• Without vitamin D supplementation for 3 months before the study.

• Serum P> 3.8 mg / dl.

• Serum Ca> 9.8 mg / dl.

• No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease).

• No exclusion criteria for the use of contrast.

Exclusion Criteria:

• Allergic reaction to sulfur hexafluoride.

• Recent unstable cardiac symptoms.

• Patients with recent coronary intervention (<7 days)

• Patients with class III and IV heart failure or severe arrhythmias.

• Severe pulmonary hypertension.